Good day, everyone, and welcome to Pfizer Pflash, a spotlight on the PD-1 VEGF bispecific PF-4404 clinical development strategy. Today's call is being recorded. At this time, I would like to turn the ...

The new hires strengthen Inimmune's leadership team and moves the company “toward key milestones and planned expansion into ...

Clinical trials are the cornerstone of drug innovation in modern medicine, providing a systematic, evidence-based framework for determining the efficacy and safety of treatments before they reach ...

SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), reports that an analyst research report was published on the Company that explains ...

Company reports encouraging monotherapy expansion data in platinum-resistant ovarian cancer and initiates first combination study with standard-of-care chemotherapies in Q1 2026 Timothy Bowler, M.D., ...

Peter Greenleaf, President, CEO & Director, opened the call announcing "strong LUPKYNIS sales in 2025, growing at a rate of 25% year-over-year" and provided 2026 sales expectations for LUPKYNIS of ...

Company is well positioned following positive FDA Type B meeting outcome, fully enrolled Phase 2 trial for its lead clinical program, and recent $5 million public offering, as commercial operation ...

As clinical development grows more complex, sponsors are rethinking how outsourcing models, technology, and partnerships align to support both speed and sustainability. The shift toward hybrid models, ...

Former Vertex executive to spearhead the clinical development of Absci’s expanding AI-designed therapeutics pipeline ...

SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that an analyst research report was published on the Company that explains ...